Evonik has announced plans to reorganise its Health Care business to focus on core growth areas such as complex active pharmaceutical ingredients (APIs), drug delivery systems, and biosolutions like lipids for mRNA and gene therapies. As part of this transformation,
Evonik has announced the expansion of its EUDRACAP portfolio with the introduction of a new functional capsule designed to deliver sensitive active ingredients, such as live biotherapeutic products (LBPs), to the ileo-colonic region. The new capsule, EUDRACAP colon, aims to
Evonik has inaugurated a new excipient manufacturing facility at its Darmstadt site, aimed at drying aqueous dispersions of its well-known EUDRAGIT polymers. The investment, a double-digit million-euro project, enhances production capacity to meet growing demand from pharmaceutical companies for oral
Evonik is partnering with KNAUER Wissenschaftliche Geräte GmbH to enhance the scale-up process for lipid nanoparticle (LNP) formulations. The collaboration aims to improve efficiency and speed up the transition from small-scale prototypes to production-scale formulations, reducing preclinical development time. The
Evonik, a global specialty chemicals company, has entered into a partnership with Interface Polymers, a UK-based materials technology company, to leverage their unique additives technology for use in plastic packaging. Here are the key takeaways from the partnership:
